C326

C326 is a novel protein therapeutic designed to inhibit the function of interleukin-6 (IL-6), a pro-inflammatory cytokine involved in immune responses and implicated in multiple disease indications. By inhibiting IL-6, C326 aims to reduce or prevent symptoms associated with autoimmunity and inflammation. It is an Avimer drug candidate, which means it has a unique structure distinct from antibodies and other therapeutic proteins; Avimer proteins are smaller than most therapeutic proteins and antibodies, offering high specificity and avidity as drug candidates. The primary indication investigated for C326 is inflammatory disorders (unspecified)[1].